OncoTherapy Science, Inc.

4564・Growth Market・Pharmaceuticals

Official website

OncoTherapy Science, Inc.

4564・Growth Market・Pharmaceuticals

Official website

OncoTherapy Science, Inc.4564

Reference Indicators

Market Cap

81¥100M

P/E (Forecast)

—

P/B

3.9x

Dividend Yield (Forecast)

0.00%

ROE

-44.0%

EV/EBITDA

—

Financial Summary

Unit: ¥M

Item	2022Mar 2022	2023Mar 2023	2024Mar 2024	2025Mar 2025	2026Mar 2026
Net Sales	1,153	1,134	610	750	808
Cost of Sales	1,039	1,093	787	762	794
Gross Profit	113	41	-177	-12	13
SG&A Expenses	436	431	265	294	289
Operating Income	-2,052	-1,106	-1,120	-797	-810
Non-operating Income	1	0	0	2	0
Non-operating Expenses	20	27	15	19	35
Ordinary Income	-2,071	-1,133	-1,136	-815	-845
Extraordinary Income	49	38	5	2	0
Extraordinary Losses	547	21	154	0	63
Pre-tax Income	-2,570	-1,116	-1,285	-813	-908
Income Taxes	1	2	2	2	2
Net Income	-2,571	-1,118	-1,288	-815	-910
EBITDA	-2,036	—	—	—	—
Gross Margin	9.9%	3.7%	-29.1%	-1.7%	1.7%
Operating Margin	-177.9%	-97.5%	-183.7%	-106.4%	-100.2%
ROA	-95.8%	-74.0%	-148.5%	-70.6%	-38.6%
ROE	-135.6%	-143.8%	-461.4%	-123.9%	-44.0%

Segment Performance

Unit: ¥M

2026

Segment	Net Sales	Operating Income	Operating Margin
「医薬品の研究及び開発」並びにこれらに関連する事業	2	-531	-26550.0%
がんプレシジョン医療関連事業	806	-55	-6.8%